Baseline characteristics of patients receiving allo-HCT after polatuzumab bridging (n = 9)
| Patient No. . | Histologic diagnosis, COO . | Age at Allo-HCT/Sex . | CAR T-cell Therapy Administered . | No. lines of therapy prior to CAR . | Response to CAR . | DOR to CAR . | No. of therapies after CAR relapse . | LDH prior to Pola (U/L) . | No. of Pola cycles . | Disease status before allo-HCT/ Best response to Pola . | Days to neutrophil/ platelet recovery . | Acute GVHD grade . | Chronic GVHD/ severity . | Relapse after Allo-HCT . | Survival/ Disease status at last follow-up . | DOR to allo-HCT (mo) . | Follow-up (mo) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | DLBCL, GCB | 46/F | LV20.19 CAR | 3 | CR | 5.1 | 1 | 323 | 2 | CR | 4/19 | 1 | 0 | N | Alive/CR | 19.5 | 19.5 |
| 2 | Transformed DLBCL, non-GCB | 66/F | Axi-cel | 3 | CR | 2.8 | 4 | 244 | 3 | CR | 17/14 | 0 | 0 | Y | Alive/CR | 12 | 24.7 |
| 3 | DLBCL, GCB | 70/M | LV20.19 CAR | 3 | PR | 2.3 | 3 | 306 | 4 | CR | 14/29 | 1 | 0 | N | Alive/CR | 32.4 | 32.4 |
| 4 | DLBCL, GCB (triple hit) | 62/M | LV20.19 CAR | 2 | PD | 0 | 1 | 283 | 3 | CR | 18/12 | 0 | 0 | N | Alive/CR | 12 | 12 |
| 5 | FL, grade 3A | 68/M | LV20.19 CAR | 3 | CR | 4.0 | 1 | 277 | 4 | PR | 17/15 | 1 | 0 | N | Alive/CR | 9.7 | 9.7 |
| 6 | DLBCL, non-GCB | 41/M | LV20.19 CAR | 3 | CR | 26.2 | 2 | 286 | 3 | CR | 16/12 | 4 | 0 | N | Alive/PR | 3.5 | 9.0 |
| 7 | DLBCL, GCB | 65/F | Axi-cel | 2 | CR | 6.5 | 1 | 192 | 3 | CR | 16/8 | 1 | Moderate | Y | Alive/CR | 29.2 | 29.2 |
| 8 | DLBCL, GCB | 72/M | LV20.19 CAR | 3 | CR | 5.9 | 1 | 213 | 3 | CR | 15/11 | 0 | 0 | N | Alive/CR | 9.6 | 9.6 |
| 9 | DLBCL, non-GCB | 66/F | Axi-cel | 3 | CR | 6.5 | 1 | 1067 | CR | 16/10 | 0 | 0 | N | Alice/CR | 4.7 | 4.7 | 9 |
| Patient No. . | Histologic diagnosis, COO . | Age at Allo-HCT/Sex . | CAR T-cell Therapy Administered . | No. lines of therapy prior to CAR . | Response to CAR . | DOR to CAR . | No. of therapies after CAR relapse . | LDH prior to Pola (U/L) . | No. of Pola cycles . | Disease status before allo-HCT/ Best response to Pola . | Days to neutrophil/ platelet recovery . | Acute GVHD grade . | Chronic GVHD/ severity . | Relapse after Allo-HCT . | Survival/ Disease status at last follow-up . | DOR to allo-HCT (mo) . | Follow-up (mo) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | DLBCL, GCB | 46/F | LV20.19 CAR | 3 | CR | 5.1 | 1 | 323 | 2 | CR | 4/19 | 1 | 0 | N | Alive/CR | 19.5 | 19.5 |
| 2 | Transformed DLBCL, non-GCB | 66/F | Axi-cel | 3 | CR | 2.8 | 4 | 244 | 3 | CR | 17/14 | 0 | 0 | Y | Alive/CR | 12 | 24.7 |
| 3 | DLBCL, GCB | 70/M | LV20.19 CAR | 3 | PR | 2.3 | 3 | 306 | 4 | CR | 14/29 | 1 | 0 | N | Alive/CR | 32.4 | 32.4 |
| 4 | DLBCL, GCB (triple hit) | 62/M | LV20.19 CAR | 2 | PD | 0 | 1 | 283 | 3 | CR | 18/12 | 0 | 0 | N | Alive/CR | 12 | 12 |
| 5 | FL, grade 3A | 68/M | LV20.19 CAR | 3 | CR | 4.0 | 1 | 277 | 4 | PR | 17/15 | 1 | 0 | N | Alive/CR | 9.7 | 9.7 |
| 6 | DLBCL, non-GCB | 41/M | LV20.19 CAR | 3 | CR | 26.2 | 2 | 286 | 3 | CR | 16/12 | 4 | 0 | N | Alive/PR | 3.5 | 9.0 |
| 7 | DLBCL, GCB | 65/F | Axi-cel | 2 | CR | 6.5 | 1 | 192 | 3 | CR | 16/8 | 1 | Moderate | Y | Alive/CR | 29.2 | 29.2 |
| 8 | DLBCL, GCB | 72/M | LV20.19 CAR | 3 | CR | 5.9 | 1 | 213 | 3 | CR | 15/11 | 0 | 0 | N | Alive/CR | 9.6 | 9.6 |
| 9 | DLBCL, non-GCB | 66/F | Axi-cel | 3 | CR | 6.5 | 1 | 1067 | CR | 16/10 | 0 | 0 | N | Alice/CR | 4.7 | 4.7 | 9 |
Axi-cel, Axicabtagene ciloleucel; COO, cell of origin; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; GCB, germinal center B; GVHD, graft-versus-host-disease; LV20.19, lentiviral anti-CD20/anti-CD19 CAR; Pola, polatuzumab; PD, progressive disease.